The consensus fair value estimate for Theravance Biopharma has shifted from about US$26.71 to roughly US$15.83 per share, a cut of around 40% that resets expectations around what the stock might be ...
Shares of Theravance Biopharma TBPH plunged 26% after the company announced the failure of the late-stage CYPRESS study ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果